If you or someone you love has stage 4 EGFR+ NSCLC, TAGRISSO may be able to help. Talk to your doctor to see if TAGRISSO may be right for you. This is not an actual patient story.
Please see full Important Safety Information at • Important Safety Infor...
Please see complete Prescribing Information, including Patient Information for TAGRISSO available at www.azpicentral.com/pi.html?p...
SELECT SAFETY INFORMATION
TAGRISSO® (osimertinib) is an FDA-approved oral targeted therapy used as a first treatment for metastatic non-small cell lung cancer with certain abnormal EGFR gene(s).
TAGRISSO may cause serious side effects. These could lead to death. Tell your healthcare provider right away if you have lung problems, such as trouble breathing, shortness of breath, cough, or fever; heart problems, such as pounding or racing, swelling of your ankles and feet, dizziness, feeling lightheaded, or feeling faint; eye problems, such as watery, red, sensitive, or painful eyes; skin problems, such as skin reactions that look like rings, or severe blistering or peeling of the skin; if you develop signs of inflammation of your blood vessels in your skin, including purple spots or redness of your skin on your lower arms, lower legs, or buttocks or large hives on the main part of your body that do not go away within 24 hours and look bruised; or if you develop signs of blood and bone marrow problems, including new fever or fever that does not go away (≥100.4 °F); easy bruising or bleeding that will not stop; unusually pale skin, infection, tiredness, or weakness. Tell your healthcare provider about all your medical conditions and any medicines you take, and if you are pregnant or plan to become pregnant or are breastfeeding.
The most common side effects of TAGRISSO alone are low white blood cell counts, low platelet counts, low red blood cell counts (anemia), diarrhea, rash, muscle, bone, or joint pain, changes in your nails, dry skin, mouth sores, and tiredness. These are not all the possible side effects.
Please see the complete Prescribing Information, including Patient Information for TAGRISSO at www.azpicentral.com/pi.html?p...
You may report side effects related to AstraZeneca products here: us-aereporting.astrazeneca.com/
This content is intended for US consumers only.
TAGRISSO is a registered trademark of the AstraZeneca group of companies.
©2024 AstraZeneca. All rights reserved. US-84975 Last Updated 3/24
1 апр 2024
